fd3ce752-3456-4aaf-bede-9cf5f0771b9d
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.400
- E2F_TARGETS+0.300
- MITOTIC_SPINDLE+0.300
- MYC_TARGETS_V1+0.300
- ANDROGEN_RESPONSE+0.200
- UV_RESPONSE_DN+0.200
- HEDGEHOG_SIGNALING+0.100
- NOTCH_SIGNALING+0.100
- PANCREAS_BETA_CELLS+0.100
- PEROXISOME+0.100
Top 10 suppressed
- ANGIOGENESIS-0.400
- APICAL_SURFACE-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- ALLOGRAFT_REJECTION-0.300
- APICAL_JUNCTION-0.300
- COAGULATION-0.300
- COMPLEMENT-0.300
- IL2_STAT5_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031592_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.878 |
| 2 | SRR1797283 | — | cohortSC | 0.872 |
| 3 | SRR13780268 | — | cohortSC | 0.864 |
| 4 | SRR5088922 | — | — | 0.856 |
| 5 | MDT-AP-0188 | Med | Medulloblastoma | 0.856 |
| 6 | SJEPD031150_D1.RNA-Seq | EPN | EPN Tumor | 0.849 |
| 7 | SJEPD031372_D1.RNA-Seq | EPN | Supratentorial EPN | 0.849 |
| 8 | SRR8942963 | — | — | 0.845 |
| 9 | SRR10900006 | — | — | 0.844 |
| 10 | TCGA-AR-A24K-01A-11R-A169-07 | — | B | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.100 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |